CAS 1095382-05-0: CCT-137690

CCT 137690 is a highly specific and oral-available aurora kinase inhibitor, for aurora A(IC50=15 nM ), B(IC50=25 nM) and C(IC50=19 nM).

CCT137690 is a chemical inhibitor, which is a synthetic compound developed through medicinal chemistry. Its primary mode of action is the selective inhibition of Cyclin-dependent kinases 8 and 19 (CDK8 and CDK19), which are part of the Mediator complex crucial for regulating transcription and gene expression. By interfering with these kinases, CCT137690 impacts the transcriptional regulation pathways that are critical for cancer cell proliferation and survival. In the context of scientific research, CCT137690 is utilized extensively for interrogating the role of CDK8 and CDK19 within cancer biology. Its application can lead to insights into how these kinases contribute to oncogenesis, offering a potential pathway for therapeutic intervention in cancers where these pathways are dysregulated. This compound serves as a tool to dissect the mechanistic role of transcriptional modulation in various cellular processes, thereby aiding in the development of targeted cancer therapies. Researchers leverage CCT137690 to explore its potential in modulating signal transduction pathways and to derive significant conclusions about its efficacy and mechanism of action in preclinical models.

CCT 137690